Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2021.04.006 http://scihub22266oqcxt.onion/10.1016/j.drudis.2021.04.006 33865979!8049177!33865979     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33865979&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Drug+Discov+Today 2021 ; 26 (10): 2214-2220 Nephropedia Template TP {{tp|p=33865979|t=2021. The fight against COVID-19: Striking a balance in the renin-angiotensin system |pdf=|usr=}}{{33865979}} gab.com Text The fight against COVID-19: Striking a balance in the renin-angiotensin system JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33865979 #FOAvip The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by interacting with membrane-bound angiotensin-converting enzyme 2 (ACE2), a vital element in the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and cardiovascular functions. We herein evaluate existing evidence for the molecular alterations within the RAS pathway (e.g., ACE2 and angiotensin II) during SARS-CoV-2 infection and subsequent Coronavirus Disease 2019 (COVID-19). This includes reports regarding potential effect of RAS blockade (e.g., ACE inhibitors and angiotensin II receptor blockers) on ACE2 expression and clinical outcomes in patients with co-morbidities commonly treated with these agents. The collective evidence suggests a dual role for ACE2 in COVID-19, depending on the stage of infection and the coexisting diseases in individual patients. This information is further discussed with respect to potential therapeutic strategies targeting RAS for COVID-19 treatment. Twit Text FOAVip The fight against COVID-19: Striking a balance in the renin-angiotensin system ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33865979 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33865979 #FOAvip English Wikipedia <ref>{{Cite pmid|33865979}}</ref> The fight against COVID-19: Striking a balance in the renin-angiotensin system #MMPMID33865979 Dean AQ; Bozza WP; Twomey JD; Luo S; Nalli A; Zhang B Drug Discov Today 2021[Oct]; 26 (10): 2214-2220 PMID33865979show ga The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by interacting with membrane-bound angiotensin-converting enzyme 2 (ACE2), a vital element in the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and cardiovascular functions. We herein evaluate existing evidence for the molecular alterations within the RAS pathway (e.g., ACE2 and angiotensin II) during SARS-CoV-2 infection and subsequent Coronavirus Disease 2019 (COVID-19). This includes reports regarding potential effect of RAS blockade (e.g., ACE inhibitors and angiotensin II receptor blockers) on ACE2 expression and clinical outcomes in patients with co-morbidities commonly treated with these agents. The collective evidence suggests a dual role for ACE2 in COVID-19, depending on the stage of infection and the coexisting diseases in individual patients. This information is further discussed with respect to potential therapeutic strategies targeting RAS for COVID-19 treatment. |Angiotensin II/metabolism[MESH] |Angiotensin-Converting Enzyme 2/genetics[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/physiopathology/*therapy[MESH] |Humans[MESH] |Renin-Angiotensin System/*drug effects[MESH]The fight against COVID-19: Striking a balance in the renin-angiotensi(epmc).pdf DeepDyve Pubget Overpricing